Yarrow Bioscience Inc
YARWAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Jun 14, 2024 | H.C. Wainwright | Joseph Pantginis | $5.75(+173%) | $2.11 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Aug 10, 2022 |
| HC Wainwright & Co. | maintain | Buy | May 7, 2021 |
Earnings History
Next report: Mar 4, 2027 · EPS est. $-27.50| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-2.14 | $-11.00 | $97.0K | $200.0K |
| May 14, 2026 | $-32.50 | $-9.00 | $86.0K | $200.0K |
| Mar 12, 2026 | $-2.50 | $-0.10 | $130.0K | $175.0K |
| Nov 6, 2025 | $-0.17 | $-0.19 | $169.0K | $125.0K |
| Aug 14, 2025 | $-6.50 | $-0.23 | $69.0K | $150.0K |
| May 8, 2025 | $-0.20 | $-0.29 | $202.0K | $50.0K |
| Mar 6, 2025 | $-0.28 | $-12.50 | $84.0K | $150.0K |
| Nov 7, 2024 | $-0.29 | $-11.50 | $121.0K | $110.0K |
News
After a brutal sell-off erased Wednesday's rally and dragged the Nasdaq back into correction territory, Wall Street analysts are still moving. Some reversed course on Pfizer, Molson Coors, and BJ's, while others spotted fresh opportunities worth a closer look.
NEW HAVEN, Conn.--(BUSINESS WIRE)--Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced that members of its executive team will participate in the following upcoming investor conferences: Guggenheim Securities 3rd Annual Healthcare Innovation Conference Date: Monday, November 9, 2026 Time: 1:30 p.m. ET Location: Boston, MA Format: Fireside chat an.
Yarrow Bioscience (NASDAQ: YARW - Get Free Report) and Atara Biotherapeutics (NASDAQ: ATRA - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership. Institutional and Insider Ownership 83.8% of Yarrow
NEW HAVEN, Conn.--(BUSINESS WIRE)--Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced the closing of its previously announced underwritten public offering of 6,634,615 shares of its common stock, including the full exercise of the underwriters' option to purchase up to 865,384 additional shares, at a public offering price per share of $26.00. Th.
NEW HAVEN, Conn.--(BUSINESS WIRE)--Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced the pricing of its previously announced underwritten public offering of 5,769,231 shares of its common stock at a public offering price per share of $26.00. The aggregate gross proceeds to Yarrow from the offering are expected to be approximately $150 million b.
NEW HAVEN, Conn.--(BUSINESS WIRE)--Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced that it has commenced an underwritten public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Yarrow expects to grant the underwriter.
NEW HAVEN, Conn.--(BUSINESS WIRE)--Yarrow Bioscience reports second quarter 2026 financial results and provides a business update.